KATIA COLLAZO: Open Payments
NPI 1205518438 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,330 in 109 payments from 11 companies in 2025. Trend: 2023 $163 · 2024 $2,285 · 2025 $2,330
Food & beverage: $2,330
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 24 | $691 |
| Fresenius USA Marketing, Inc. | 32 | $543 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $217 |
| AKEBIA THERAPEUTICS INC | 7 | $200 |
| Lilly USA, LLC | 10 | $197 |
| Amgen Inc. | 14 | $159 |
| ABIOMED | 1 | $94 |
| Novartis Pharmaceuticals Corporation | 3 | $77 |
| Calliditas Therapeutics US Inc. | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
Products named: VELPHORO, IBSRELA, JARDIANCE, XPHOZAH 30 MG, Vafseo, KRYSTEXXA, TARPEYO, JYNARQUE.
Industry payments across CA — which companies pay providers there.
